排名前五的靶点	数量

α-synuclein(α-突触核蛋白)	3
TfR1(转铁蛋白受体1)	2
NPAS2(neuronal PAS domain protein 2)	2
CCR2(C-C趋化因子受体2型)	1
CB2(大麻素受体CB2)	1

关联

项与 University of California, Los Angeles 相关的药物

Gallium GA-68 Gozetotide

镓[68Ga]戈泽肽

靶点

PSMA

作用机制

PSMA抑制剂

在研机构

Mayo Clinic [+12]

原研机构

The University of California, San Francisco

在研适应症

PSMA阳性前列腺癌 [+15]

非在研适应症

骨转移癌 [+3]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-12-01

Naltrexone

纳曲酮

靶点

Opioid receptors x μ opioid receptor

作用机制

Opioid receptors拮抗剂 [+1]

在研机构

The Children's Mercy Hospital [+13]

原研机构

Alkermes, Inc.

在研适应症

鸦片依赖 [+13]

非在研适应症

获得性免疫缺陷综合征 [+34]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2006-04-13

Rituximab

利妥昔单抗

靶点

CD20

作用机制

CD20抑制剂 [+3]

在研机构

Roche Holding AG [+44]

原研机构

Genentech, Inc.

在研适应症

心脏移植排斥反应 [+145]

非在研适应症

急性双系白血病 [+143]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1997-11-26

1,621

项与 University of California, Los Angeles 相关的临床试验

NCT03883360

/ Withdrawn临床2期IIT

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of Δ9-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.

开始日期2050-01-01

申办/合作机构

University of Maryland Baltimore

[+2]

NCT07022574

/ Not yet recruitingN/AIIT

Evaluating the Impact of Autoimmune Protocol Diet on Proteinuria in Patients With IgA Nephropathy

This study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Nephropathy (IgAN), a common kidney disease that can lead to kidney failure. The AIP diet avoids foods that may cause inflammation (like dairy, grains, and sugar) for 8 weeks, then gradually reintroduces them over 4 months. We're enrolling 30 adults aged 18-65 with IgAN and protein in their urine to try this diet for 6 months. Participants will track their urine protein daily at home, keep a food log, and have monthly lab checkups, with support from a diet expert. The main goal is to see if the diet reduces urine protein by 20% or more, which could slow disease progression and reduce the need for treatments like dialysis. This exploratory study aims to find out if diet changes can help manage IgAN.

开始日期2026-02-01

申办/合作机构

University of California, Los Angeles

NCT04846517

/ Not yet recruitingN/AIIT

Multilocus Repetitive Transcranial Magnetic Stimulation for Anorexia Nervosa (MULTI-REX): A 4-week Open-Trial Pilot Study

This study will examine the feasibility of off-label multilocus repetitive transcranial magnetic stimulation (rTMS) for symptoms of Anorexia Nervosa in participants between the ages of 14-24. rTMS is a non-invasive, brain-based intervention that uses magnets to deliver energy to the brain. The investigators will also see if patients receiving multilocus rTMS show any improvements in their eating disorder, mood, anxiety, and obsessions and compulsions (if present). Participants will receive daily intervention with off-label multilocus rTMS for 20 total treatments. Participants will also be asked to complete mental health and well-being surveys, physical measurements, and 2 brain imagining scans (MRIs) at baseline, and at study end. The investigators will also ask participants to complete surveys are 1-month and 3-months after the final rTMS session. The target enrollment for this study is 45 participants.

开始日期2026-01-30

申办/合作机构

University of California, Los Angeles

100 项与 University of California, Los Angeles 相关的临床结果

登录后查看更多信息

0 项与 University of California, Los Angeles 相关的专利（医药）

登录后查看更多信息

162,886

项与 University of California, Los Angeles 相关的文献（医药）

2026-01-01·ANNALS OF VASCULAR SURGERY

One-Year Functional Patency and Comparison of Superficialization Techniques for Brachiobasilic Arteriovenous Fistulas

Article

作者: Sandigo-Saballos, Isabela ; Hurwitz, Mikayla ; Valadez, Maria ; Archie, Mark ; Ugarte, Ramsey ; Montero Arcila, Veronica ; de Virgilio, Christian

BACKGROUND:

Superficialization of brachiobasilic arteriovenous fistulae (BBAVFs) is generally performed by either creating a shelf or dividing, tunneling, and transposing the vein with reanastomosis. This multiinstitutional study evaluates the impact of these techniques and other variables on BBAVF functional patency at 12 months.

METHODS:

A retrospective review of patients who underwent two-stage BBAVF between 2014 and 2019 with at least 1-year follow-up was conducted from 5 safety net hospitals. The primary end point was functional patency at 12 months. Bivariate and multivariate logistic regression models evaluated the relationship between preoperative and intraoperative variables and fistula function at 12 months.

RESULTS:

There were 260 patients with an overall 12-month functional patency rate of 71.5%. Use of aspirin (odds ratio [OR] 1.858, 95% confidence interval [CI] 1.023-3.372, P = 0.042) and intraoperative anticoagulation (OR 2.118, 95% CI 1.193-3.760, P = 0.01) at the first stage procedure, and previous arteriovenous fistula or graft (OR 0.465, 95% CI 0.233-0.928, P = 0.030), were associated with functional patency at 12 months. When comparing shelfing versus transposition techniques, there was no significant difference in the functional patency rates (83.6% vs. 89.9%, P = 0.179), although the shelfing technique was associated with a higher rate of postoperative complications (19.8% vs. 9.0%, P = 0.027).

CONCLUSION:

In patients undergoing 2-stage BBAVF, the use of aspirin and intraoperative heparin at the first stage procedure are associated with higher functional patency at 12 months. Functional patency was similar for the shelfing technique versus transposition at the second stage. The shelfing technique was associated with higher rates of postoperative complications, primarily related to wound healing.

2026-01-01·Neural Regeneration Research

Microglia and macrophages in brain injury and repair after subarachnoid hemorrhage

Article

作者: Magaki, Shino D. ; Vinters, Harry V. ; Lauzier, David C.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

作者: Behling, Michael ; Atwater, Amber Reck ; Schlesinger, Todd ; Pierce, Evangeline ; Blauvelt, Andrew ; Burge, Russel ; ElMaraghy, Hany ; Kircik, Leon ; Armstrong, April

BackgroundLebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.ObjectiveTo evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc anal.).MethodsIn the 52-wk (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive s.c. lebrikizumab 250 mg or placebo every 2 wk.Investigator Global Assessment (IGA) 0/1 and improvements in QoL outcomes were assessed at W16 among lebrikizumab-treated patients.ResultsAt W16, 564 patients were categorized by EASI response (EASI <50: 32.8%; EASI ≥50-<75: 13.8%; EASI ≥75-<90: 20.2%; EASI ≥90: 33.2%).Patients with higher EASI responses showed higher IGA 0/1 response rates (EASI ≥75-<90: 37.7% and EASI ≥90: 86.1%).Pruritus NRS (least squares mean range: -1.5 to -4.4), sleep-loss score (-0.6 to -1.6), and Dermatol. Life Quality Index (-3.3 to -10.6) improved across EASI response categories (p < 0.001).Anxiety and depression scores improved for most EASI response categories (p < 0.01).ConclusionLebrikizumab-treated patients with moderate-to-severe AD showed improved symptoms and QoL across EASI response categories at W16, with greater improvements observed in patients with higher EASI responses.

1,421

项与 University of California, Los Angeles 相关的新闻（医药）

2025-07-05

·生物世界

华人学者本周发表4篇Cell论文：高度血管化的肺/肠道类器官；修复血管性痴呆；自身免疫病新疗法；同义突变调控性状

撰文丨王聪编辑丨王多鱼排版丨水成文本周（6 月 30-7 月 6 日），国际顶尖学术期刊 Cell 共上线了 5 篇研究论文，其中 4 篇来自华人学者，这些研究分别构建高度血管化的肺类器官和肠道类器官、发现血管性痴呆的大脑修复机制、开发LAG-3/TCR双抗，治疗T细胞驱动的自身免疫病、揭示同义突变通过表观转录组调控赋予黄瓜驯化性状。高度血管化的肺类器官和肠道类器官2025 年 6 月 30 日，辛辛那提儿童医院/加州大学洛杉矶分校顾名夏团队和辛辛那提儿童医院郭敏哲团队合作，在国际顶尖学术期刊 Cell 上发表了题为：Co-development of Mesoderm and Endoderm Enables Organotypic Vascularization in Lung and Gut Organoids 的研究论文。该研究首次通过人类诱导多能干细胞（iPSC）成功构建了高度血管化的肺类器官和肠道类器官。这些类器官模型不仅模拟了人类胚胎早期多胚层协同发育的复杂过程，更突破了传统类器官缺乏功能性血管和器官特异性间充质的瓶颈，为研究人类器官发育和疾病中的复杂细胞间通讯以及再生医学提供了一个先进的平台。论文第一作者兼共同通讯作者苗一非博士，现为中国科学院动物研究所人类器官生理病理模拟装置（HOPE）研究员；共同第一作者谈诚博士现为北京大学人民医院妇产科主治医师。发现血管性痴呆的大脑修复机制2025 年 6 月 30 日，加州大学洛杉矶分校 S. Thomas Carmichael 团队（博士后田敏为第一作者）在国际顶尖学术期刊 Cell 上发表了题为：Deconstructing the intercellular interactome in vascular dementia with focal ischemia for therapeutic applications 的研究论文。血管性痴呆（VaD）是仅次于阿尔茨海默病（AD）的痴呆症第二大病因，主要是一种白质缺血性疾病，目前尚无直接疗法，病变部位内的细胞间相互作用决定着疾病的进展或修复。该研究结合小鼠模型和人类数据，确定了血管性痴呆的大脑修复的关键信号通路——CD39-A3AR，并证明了一种处于 3 期临床试验阶段的治疗银屑病的 A3AR 特异性激动剂——Piclidenoson，能够促进大脑组织的修复，并恢复记忆和步态功能。有望为血管性痴呆这种研究不足的主要痴呆类型带来首个有效治疗方法。LAG-3/TCR双抗，治疗T细胞驱动的自身免疫病2025 年 6 月 30 日，纽约大学格罗斯曼医学院王俊教授团队联合中国科学院生物物理研究所娄继忠研究员团队、浙江大学医学院陈伟教授团队（Jasper Du、陈辉、由佳为共同第一作者），在国际顶尖学术期刊 Cell 发表了题为：Proximity between LAG-3 and the T Cell Receptor Guides Suppression of T Cell Activation and Autoimmunity 的研究论文。该研究首次系统性揭示了 LAG-3 抑制受体由其经典配体 MHC-II 调控的条件性激活机制：LAG-3 并非简单依赖配体结合本身，而是依赖 MHC-II 介导的 TCR 空间邻近效应，使 LAG-3 与 TCR 复合物形成顺式共定位，从而实现对 CD4+ T 细胞的有效抑制。这一发现颠覆了人们对免疫检查点（特别是LAG-3）激活机制的传统认知。LAG-3 对激活条件的高度依赖性，意味着其在体内难以被有效触发；但这也为精准干预自身免疫性 T 细胞提供了独特机会。基于这一机制，王俊团队创新性地开发了靶向 LAG-3 与 TCR 的双特异 T 细胞抑制抗体（Bispecific T cell silencer，BiTS），可特异性调控 LAG-3 阳性的致病性 T 细胞，并在多种自身免疫疾病动物模型中展现出显著的治疗效果。同义突变通过表观转录组调控赋予黄瓜驯化性状2025 年 7 月 1 日，中国农业科学院蔬菜花卉研究所杨学勇研究员、中国农业科学院（深圳）农业基因组研究所黄三文院士、英国约翰英纳斯研究中心丁一倞研究员作为共同通讯作者（中国农业科学院蔬菜花卉研究所辛同旭博士、河南大学张震副教授、英国约翰英纳斯中心张月莹博士和中国农业科学院蔬菜花卉研究所已毕业硕士生李旭彤为共同第一作者），在国际顶尖学术期刊 Cell 上发表了题为：Recessive epistasis of a synonymous mutation confers cucumber domestication through epitranscriptomic regulation 的研究论文。该研究首次在遗传学上证明了同义突变可通过改变 m6A 修饰和 mRNA 结构构象来调控驯化的重要性状。这一发现挑战了传统认知，同时凸显出同义突变在作物改良策略中可能具有重要价值。未来深入研究同义突变在 RNA 修饰与结构调控中的功能，有望为作物改良开辟新的路径。论文链接：1. https://www.cell.com/cell/abstract/S0092-8674(25)00628-22. https://www.cell.com/cell/fulltext/S0092-8674(25)00636-13. https://www.cell.com/cell/abstract/S0092-8674(25)00638-54. https://www.cell.com/cell/fulltext/S0092-8674(25)00674-9设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

免疫疗法

2025-07-03

·药事纵横

从古老魔法到现代医学，Compass Pathways裸盖菇素疗法III期临床达主要终点

植物、真菌、细菌的次级代谢物是新药开发的重要资源，裸盖菇素即是其中之一，它是一种是蘑菇产生的吲哚类次级代谢物，化学名为 4 -磷氧基- N,N-二甲基色胺。南美阿兹特克人将其用于宗教和治疗仪式，称“teonanacatl”（神的肉）。西班牙传教士曾试图销毁其使用证据，但16世纪文献记载促使20世纪学者探索其身份。1957年西方杂志报道揭示其用途，后经标本获取与成分分析实现化学合成。近10-15年，FDA批准的临床研究表明，裸盖菇素在抑郁症、焦虑症及多种成瘾等一系列中枢神经系统疾病方面具有一定的潜力。裸盖菇素研究进程裸盖菇素是在1958年由山德士化学家阿尔伯特・霍夫曼首次分离合成确定了裸盖菇素的结构，并于1960年由山德士制药以“Indocybin” 的名称推向市场用于心理疾病治疗的辅助药物，1966年该公司停止销售该药物，由于该药物存在致幻作用，1971年联合国《精神药物公约》将裸盖菇素列入严格管控名单，该药物研究受限，直到20世纪初才重新兴起。2006年美国亚利桑那大学Moreno 等人报道了一项开放标签研究，旨在研究裸盖菇素在9名OCD患者中的安全性、耐受性及临床效果，部分患者症状急性减轻；Grob等人首次通过安慰剂对照试验证实裸盖菇素的治疗效果：2011年加州大学洛杉矶分校对12名晚期癌症伴焦虑患者施用中等剂量（0.2 mg/kg），6 个月随访显示，状态-特质焦虑量表（STAI）评分在 1-3个月时显著降低，贝克抑郁量表（BDI）评分在6个月时显著改善，证实了中等剂量的安全性和可行性；2014年Johnson等人在开放标签试点研究中，将裸盖菇素（20或30 mg/70 kg）纳入15周戒烟治疗方案，15名尼古丁依赖者中80%在6个月随访时实现7天戒断；2015年Bogenschutz 等人对 10 名 DSM-IV 酒精依赖者进行裸盖菇素辅助心理治疗，发现施用后戒断率显著提升，且效果维持至36周；2016年《柳叶刀》杂志发表一篇裸盖菇素治疗难治性抑郁症的研究，同年裸盖菇素在癌症患者抑郁和焦虑方面的治疗有了突破性进展，Griffiths等人对51名癌症患者进行双盲交叉试验，高剂量裸盖菇素（22-30 mg/70 kg）显著降低抑郁和焦虑评分，提升生活质量和乐观态度，6个月后80%患者仍维持疗效。Ross等人对29名患者的双盲对照试验显示，裸盖菇素（0.3 mg/kg）快速缓解焦虑和抑郁，改善生存质量和对死亡的态度，6.5个月后60-80% 患者持续获益；2018年，FDA授予裸盖菇素用于治疗难治性抑郁症（TRD）的突破性疗法称号，并于2019年授予重度抑郁症（MDD）的突破性疗法认定。裸盖菇素作用机制裸盖菇素是一种天然存在的植物生物碱，发现于裸盖菇属蘑菇中。裸盖菇素进入体内后迅速去磷酸化成为具有精神活性的裸盖菇辛，裸盖菇辛进入体循环并穿过血脑屏障，作用于大脑皮层的5 -羟色胺2A受体，该受体密集表达于皮层锥体细胞的顶端树突上，可在大脑中引发下游效应，包括神经递质（如多巴胺、谷氨酸）释放变化，进而调节感知、情绪、思维及焦虑/欣快症状，持续时间可达4-6h。COMPASS Pathways的裸盖菇素疗法Compass公司开发了一种名为 COMP360 的研究性合成裸盖菇素制剂，用于治疗某些严重心理健康疾病包括难治性抑郁症、创伤后应激障碍和神经性厌食症。难治性抑郁症（TRD）是指患有重度抑郁症的人对至少两种不同的治疗没有充分反应的情况， COMP360已被美国食品药品监督管理局（FDA）指定为突破性疗法，并在英国获得创新许可与获取通道（ILAP）认定，用于治疗难治性抑郁症（TRD）。裸盖菇素制剂的I期临床试验是在89名健康人中于2019年完成的，IIb期随机对照试验共有233名受试者入组，旨在探索COMP360治疗难治性抑郁症的安全性和有效性，剂量为25 mg、10 mg 或 1 mg（对照）以及心理支持，最高剂量组25mg达到了主要研究终点，给药3周后，25mg剂量组约30%患者病情得到缓解，并显示出统计学意义和临床相关性的抑郁症状严重程度的降低和快速持久的治疗反应，安全性方面233名受试者中有179名（77%）发生不良事件，包括头痛、恶心和头晕，与既往研究一致。关于COMP360III期临床计划，旨在评估 COMP360 裸盖菇素的安全性和有效性。有两项关键 III 期试验 COMP005 和 COMP006，评估COMP360用于治疗难治性抑郁症（TRD）的疗效。Compass Pathways plc在2025.06.23宣布，正在进行的 III 期 COMP005 试验成功达到主要终点，在美国32个中心为 258 名难治性抑郁症患者给药，旨在评估单剂量 25 mg COMP360 与安慰剂相比在降低 TRD 症状严重程度方面的有效性和安全性，单剂量 25 mg COMP360 与安慰剂相比，蒙哥马利-奥斯伯格抑郁评分量表(MADRS)平均治疗差异为-3.6分，p<0.001。根据对005和006研究数据的最新审查，安全性发现与之前的COMP360 研究一致，没有新的或意外的安全发现，COMP005 试验第6周的阳性顶线结果凸显了裸盖菇素治疗在精神卫生保健中的创新潜力。与COMP005试验并行进行的 COMP006 试验是一项随机、双盲研究，计划从北美和欧洲招募568名参与者，旨在比较间隔三周服用的两种固定剂量25 mg COMP360与10 mg COMP360和1 mg COMP360的安全性和有效性。Compass Pathways表示计划与美国食品药品监督管理局讨论COMP005的初步数据，FDA尚未对这些结果进行审查，Compass预计在COMP006试验的所有参与者完成后的第9周分享COMP005的26周数据，COMP006的26周数据计划在 2026年下半年公布。III期临床的积极结果标志着 TRD 患者的一个重要里程碑，对迷幻药的临床研究具有重大意义，当我们开始了解其背后的大脑机制，并开始利用这些机制造福人类时，科学就将超越迷幻，这不是魔法，而是一种艰难的工作。1、https://www.biospace.com2、https://compasspathways.com3、Geiger H A , Wurst M G , Nathan D R .Dark Classics in Chemical Neuroscience: Psilocybin.[J].AcsChemicalNeuroscience,2018:acschemneuro.8b00186-.DOI:10.1021/acschemneuro.8b00186.4、Goodwin G M, Aaronson S T, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression[J]. New England Journal of Medicine, 2022, 387(18): 1637-1648药事纵横投稿须知：稿费已上调，欢迎投稿

临床3期突破性疗法临床结果

2025-07-01

·PRNewswire

NEW STUDY SHOWS SNACKING ON MIXED TREE NUTS MAY IMPACT CARDIOVASCULAR RISK FACTOR TMAO

New Findings Published in Nutrients in Partnership with the International Tree Nut Council Nutrition Research & Education Foundation DAVIS, Calif., July 1, 2025 /PRNewswire/ -- In a paper1 published online this week in the journal, Nutrients, researchers found that consuming mixed tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) in a hypocaloric diet resulted in reduced body weight and plasma levels of the cardiovascular risk factor trimethylamine N-oxide (TMAO). The decrease in TMAO levels was greatest among individuals with lower-quality baseline diets. In a previous study2, researchers at UCLA demonstrated that consuming 1.5 ounces of tree nuts per day (versus pretzels) during 24 weeks of weight loss and weight maintenance, resulted in weight loss, and decreased blood pressure and heart rate—signs of reduced cardiovascular risk. TMAO, a gut microbiome metabolite, is a novel cardiovascular disease risk factor. It is produced by the liver from trimethylamine (TMA), which is generated by gut bacteria from dietary precursors such as choline, phosphatidylcholine and L-carnitine. Diet can impact TMAO levels by modifying the gut microbiota, effecting the production of TMA from nutrients like choline and L-carnitine. Tree nuts, which are rich in phytochemicals such as carotenoids, phenolic acids and phytosterols, may also affect TMAO production. The current study looked at whether tree nut snacks, as part of a hypocaloric diet, could influence TMAO levels and their relationship with the gut microbiome. Plasma samples were collected and evaluated from 95 overweight or obese participants. Nutritional data were collected at baseline and week 12 via dietary recall. Each study participant was given a Healthy Eating Index (HEI) score, which is used to assess diet quality based on the Dietary Guidelines or Americans. According to lead researcher, Zhaoping Li, MD, PhD, Professor of Medicine and Chief of the Division of Clinical Nutrition at UCLA, "While the hypocaloric diet with tree nuts and pretzels both resulted in a significant reduction in plasma TMAO levels, the reduction of TMAO was more profound in those consuming mixed tree nuts with poor dietary habits and low HEI scores." Interestingly, the dietary intervention did not significantly alter the intake of dietary sources of TMAO, including choline and phosphatidylcholine. Therefore, the observed decrease in TMAO plasma levels is unlikely due to a reduction in TMAO precursors. "Adding mixed tree nuts to hypocaloric diets may not only help in the reduction of plasma TMAO levels, but may be an important intervention for managing cardiovascular health," stated Dr. Li. In support of these findings, Maureen Ternus, M.S., R.D., Executive Director of the International Tree Nut Council Nutrition Research & Education Foundation (INC NREF), emphasized, "This study is yet another piece of evidence showing that people should include more nuts in their diet. Just a handful of tree nuts (1.5 ounces or 1/3 cup) every day can result in numerous health benefits." The International Tree Nut Council Nutrition Research & Education Foundation (INC NREF) is a non-profit, non-governmental organization dedicated to supporting nutrition research and education for consumers and health professionals throughout the world. Members include those associations and organizations that represent the nine tree nuts (almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts). For more information, please visit our website at . 1 Lei, O., J. Yang, H.H. Kang, Z. Li., 2025. Impact of a 12-week hypocaloric weight loss diet with mixed tree nuts vs. pretzels on trimethylamine-n-oxide (TMAO) levels in overweight adults. Nutrients 17(13): 2137. 2 Wang, J., S. Wang, S.M., Henning, T. Qin, Y. Pan, J. Yang, J. Huang, C.-H. Tseng, D. Heber, Z. Li., 2021 Mixed tree nut snacks compared to refined carbohydrate snacks resulted in weight loss and increased satiety during both weight loss and weight maintenance: a 24-week randomized controlled trial. Nutrients. 13(5), 1512. SOURCE International Tree Nut Council Nutrition Research & Education Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果

100 项与 University of California, Los Angeles 相关的药物交易

登录后查看更多信息

100 项与 University of California, Los Angeles 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年07月24日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

镓[68Ga]戈泽肽 ( PSMA )	前列腺癌更多	批准上市
CCX-140 ( CCR2 )	糖尿病肾病更多	临床2期
Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles) ( CD34 )	腺苷脱氨酶缺乏更多	临床1/2期
CoTend-BXBB(Tendel Therapies)	新型冠状病毒感染更多	临床1/2期
NADPH oxidase gene therapy(Généthon) ( NOX1 )	慢性肉芽肿病更多	临床1/2期